Why the study?
The relationship between MAFLD and maternal complications poses a significant health threat, yet pregnant women are severely underrepresented in clinical research.
This review highlights the significant health threat of MAFLD in pregnancy, emphasizing the need for fair inclusion of pregnant women in clinical trials and better clinical management.
MAFLD in pregnancy signals elevated maternal risks; leaves open the need for prospective interventional trials.
The intricate relationship between metabolic-associated fatty liver disease (MAFLD) and maternal complications has rapidly become a significant health threat in pregnant women. The presence of MAFLD in pregnancy increases the maternal risk of metabolic complications and comorbidities for both mother and baby. The preexistence or development of MAFLD in pregnancy is a complex multifactorial disorder that can lead to further complications for mother and baby. Therefore, as pregnant women are severely underrepresented in clinical research, there is a great need for a fair inclusion of this group in clinical trials. This review aims to explore the effects of MAFLD during pregnancy in the context of maternal complications and outcomes and explore the effects of pregnancy on the development and progression of MAFLD within the context of maternal obesity, altered metabolic profiles, gestational diabetes and altered hormonal profiles. We also addressed potential implications for the presence of MAFLD during pregnancy and its management in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Fouda et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: